E-DRUG: New Book: Pharmaceutical policy in countries with developing healthcare systems
-------------------------------------------------------------------------------------------------
Dear E-druggers
I would like to draw your attention to this recently released book by Adis/Springer. The book is a 430 page text with seventeen country case studies and three synthesis chapters, it covers various aspects of pharmaceutical policy and practice. If your academic institution has access to Springer Databases then the soft copy of the book can be downloaded through it.
Book Details
Title: Pharmaceutical Policy in Countries with Developing Healthcare Systems
Editor: Zaheer-Ud-Din Babar
Publisher: Springer Nature 2017
ISBN: 978-3-319-51672-1
Length: 430 pages
BABAR, Z.U D (Ed). Pharmaceutical Policy in Countries with Developing Healthcare Systems
A comprehensive and granular insight into the challenges of promoting rational medicine, this book serves as an essential resource for health policy makers and researchers interested in national medicines policies. Country-specific chapters have a common format, beginning with an overview of the health system and regulatory and policy environments, before discussing the difficulties in maintaining a medicine supply system, challenges in ensuring access to affordable medicines and issues impacting on rational medicine use. Numerous case studies are also used to highlight key issues and each chapter concludes with country-specific solutions to the issues raised. Written by highly regarded academics, the book includes countries in Africa, Asia, Europe, the Middle East and South America.
Electronic link
http://www.springer.com/gb/book/9783319516721
Table of Contents
1. Introduction ( Synthesis of Chapters) Helle Håkonsen, Isabel Emmerick, and Zaheer-Ud-Din Babar
Part I Low and Lower Middle Income Countries
2. Pharmaceutical Policy in the East African Community: Burundi, Kenya, Uganda, Rwanda, Tanzania Jane Mashingia and Aarti Patel
3. Pharmaceutical Policy in Pakistan Muhammad Atif, Mahmood Ahmad, Quratulain Saleem, Louise Curley, Muhammad Qamar-uz-Zaman, and Zaheer-Ud-Din Babar
4. Pharmaceutical Policy in the Philippines Douglas Ball and Roderick Salenga
5. Pharmaceutical Policy in Vietnam Tuan Anh Nguyen, Agnes Vitry, and Elizabeth E. Roughead
Part II Upper Middle Income Countries
6. Pharmaceutical Policy in Argentina Claudia Marcela Vargas-Pelaez, María Teresa Bürgin Drago, Angela Acosta, and Mareni Rocha Farias
7. Pharmaceutical Policy in Brazil Vera Lucia Luiza, Maria Auxiliadora Oliveira, Gabriela Costa Chaves, Matthew B. Flynn, and Jorge Antonio Zepeda Bermudez
8. Pharmaceutical Policy in Bulgaria Ruth Lopert
9. Pharmaceutical Policy in China Yu Fang
10. Pharmaceutical Policy in Colombia Adriana Mendoza-Ruiz, Angela Acosta, Egdda Patricia Vanegas Escamilla, and María Cristina Latorre Torres
11. Pharmaceutical Policy in Ecuador Carlos E. Durán, Ruth Lucio, and Joan Rovira
12. Pharmaceutical Policy in Jordan Faris El-Dahiyat and Louise Elizabeth Curley
13. Pharmaceutical Policy in Russia
14. Pharmaceutical Policy in South Africa Fatima Suleman and Andy Gray
Part III High Income Countries
15. Pharmaceutical Policy in Poland Irmina Wlodarczyk and Shane L. Scahill
16. Pharmaceutical Policy in Saudi Arabia Alian A. Alrasheedy, Mohamed Azmi Hassali, Zhi Yen Wong, Hisham Aljadhey, Saleh Karamah AL-Tamimi, and Fahad Saleem
17. Pharmaceutical Policy in Trinidad and Tobago Sameer Dhingra, Sandeep Maharaj, Rian Marie Extavour, and Zaheer-Ud-Din Babar
18. Pharmaceutical Policy in the UAE Ranya Hassan, Hafiz Alam Sher, Rabia Khokhar, and Rabia Hussain
Part IV Further Perspectives
19. "Repurposing" Medicines: A Case for Low- and Middle-Income Countries with Developing Healthcare Systems Warren Kaplan
20. Pharmaceutical Policy in Countries with Developing Healthcare Systems: Synthesis of Country Case Studies Warren Kaplan, Nikolina Boskovic, Daniel Flanagan, Serafina Lalany, Chia-Ying Lin, and Zaheer Ud-Din Babar
Foreword of the book (Alessandra Ferrario, London School of Economics and Political Sciences)
The publication of this book is very timely. The 2016 Lancet Commission on Essential Medicines Policies Report provided many country's examples, concrete
recommendations, and an evaluation framework that can be used to improve access to essential medicines.
The 2016 United Nations Secretary-General's High-Level
Panel on Access to Medicines Report specifically addressed the misalignment between the right to health, intellectual property, and trade. This book provides a
wealth of experience to inform policy decisions that countries will need to take to improve access to medicines.
The chapters in this book are written by country experts, who often have had first-hand experience in introducing and implementing policy change, under the
experienced editorial guidance of Professor Zaheer-Ud-Din Babar. This book is therefore a unique asset for policy-makers, health professionals,academics, researchers, and students wishing to learn from the experience of a wide range of countries, which have taken bold steps in trying to improve access to medicines
by embarking on the arduous, but potentially rewarding, path of pharmaceutical policy reform.
Kind Regards
Zaheer
Zaheer-Ud-Din Babar, PhD
Professor in Medicines and Healthcare
Department of Pharmacy, University of Huddersfield, Queensgate, HD1 3DH
Huddersfield, United Kingdom
https://www.hud.ac.uk/ourstaff/profile/index.php?staffid=1610
Editor-in-Chief
Journal of Pharmaceutical Policy and Practice
Email: z.babar@hud.ac.uk